96 related articles for article (PubMed ID: 8187800)
1. Disk susceptibility testing for rufloxacin.
Andrews JM; Wise R
Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):974-6. PubMed ID: 8187800
[No Abstract] [Full Text] [Related]
2. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
Qadri SM; Ayub A; Ueno Y; Saldin H
Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
[TBL] [Abstract][Full Text] [Related]
3. Breakpoint determination: rufloxacin.
Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):574-5. PubMed ID: 8404928
[No Abstract] [Full Text] [Related]
4. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
Wise R; Andrews JM; Matthews R; Wolstenholme M
J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
[TBL] [Abstract][Full Text] [Related]
6. Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
Fuchs PC; Barry AL; Pfaller MA
J Clin Microbiol; 1993 Aug; 31(8):2236-7. PubMed ID: 8396592
[TBL] [Abstract][Full Text] [Related]
7. Rufloxacin enhances susceptibility of Escherichia coli to leukocyte activity.
Herrera I; Martinez P; Perez P; Martin M; Gomez-Lus ML; Prieto J
J Chemother; 1995 Nov; 7 Suppl 4():36-7. PubMed ID: 8904099
[No Abstract] [Full Text] [Related]
8. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of rufloxacin with five other antimicrobial agents against bacterial enteric pathogens.
Soriano F; Fernández-Roblas R; López JC; García-Corbeira P; Aguilar L
J Antimicrob Chemother; 1994 Jul; 34(1):157-60. PubMed ID: 7961202
[No Abstract] [Full Text] [Related]
10. Comparison of rufloxacin and norfloxacin effects on faecal flora.
Marco F; Giménez MJ; Jiménez de Anta MT; Marcos MA; Salvá P; Aguilar L
J Antimicrob Chemother; 1995 Jun; 35(6):895-901. PubMed ID: 7559202
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
Piddock LJ; Panchal S; Norte V
J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of anaerobic bacteria to temafloxacin.
Southern PM; Patel S
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S334. PubMed ID: 8391861
[No Abstract] [Full Text] [Related]
13. A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens.
Schito GC; Acar JF; Bauernfeind A; Duval J; Finch RG; Focht J; Nicoletti G; Phillips I; Pratts G; Soriano F; Wiedeman B; Wise R
J Antimicrob Chemother; 1996 Oct; 38(4):627-39. PubMed ID: 8937958
[TBL] [Abstract][Full Text] [Related]
14. Selection of a fluoroquinolone-class disk for susceptibility tests.
Barry AL; Fuchs PC
Am J Med; 1993 Mar; 94(3A):17S-22S. PubMed ID: 8383918
[TBL] [Abstract][Full Text] [Related]
15. Favourable effects of sub-MIC rufloxacin concentrations in decreasing the pathogen-host cell adhesion.
Braga PC; Piatti G
Pharmacol Res; 1993; 28(1):11-9. PubMed ID: 8234142
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.
Mattina R; Cocuzza CE; Cesana M; Bonfiglio G
Chemotherapy; 1991; 37(4):260-9. PubMed ID: 1665122
[TBL] [Abstract][Full Text] [Related]
17. [Synthesis and antibacterial activity of tricycic fluoroquinolones].
Xiong WN; Wang EH
Yao Xue Xue Bao; 1997 May; 32(5):347-52. PubMed ID: 11498869
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
Renaudin H; Bébéar C
Drugs; 1995; 49 Suppl 2():243-5. PubMed ID: 8549318
[No Abstract] [Full Text] [Related]
19. Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ-free mice model.
Gismondo MR; Drago L; Lombardi A; Fassina C; Cesana M
Chemotherapy; 1995; 41(4):281-8. PubMed ID: 7555209
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of MF 5137, a new potent 6-aminoquinolone.
Wise R; Pagella PG; Cecchetti V; Fravolini A; Tabarrini O
Drugs; 1995; 49 Suppl 2():272-3. PubMed ID: 8549329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
